Nasal vaccines
NOSEVAC
at a glance
TARGET
Upper respiratory tract pathogens
TIMELINE
1 May 2023 to 30 April 2028
COORDINATOR
European Vaccine Initiative
FUNDER
European Union, UKRI and SERI
FUNDING
€11.1 Mio Euro
SUMMARY
Innovative nasal vaccines to prevent pathogen colonization and infection in the upper respiratory tract
NOSEVAC project focuses on four major respiratory pathogens: Streptococcus pneumoniae or pneumococcus, Bordetella sp., influenza virus, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for diseases with major impact on public health: community-acquired pneumonia (CAP), whooping cough, influenza and Coronavirus Disease 2019 (COVID-19), respectively.
NOSEVAC aims to combine innovative formulations and manufacturing processes to deliver and evaluate bivalent RNA- and protein-based nasal vaccines against bacterial and viral infection, respectively.
PARTNERS
• Associação do Instituto Superior Técnico para a Investigação e Desenvolvimento, (IST-ID)
• Epithelix (Epithelix)
• ErasmusMC (EMC)
• European Vaccine Initiative (EVI)
• Istituto Superiore di Sanità (ISS)
• Institut Pasteur de Lille (IPL), INSERM
• Quantoom Biosciences (UQTM)
• University of Geneva (UNIGE)
• University of Lausanne (UNIL)
• University of Lille (ULILLE)
• University of Oxford (UOXF)
• University of Santiago de Compostela (USC)
• Veterna S.r.l. (Veterna srl)
Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency. Neither the European Union nor the granting authority can be held responsible for them.